Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharma a/s - dexlansoprazole - capsules modified release - 30 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharma a/s - dexlansoprazole - capsules modified release - 60 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - vedolizumab 300mg;  ;   - powder for injection - 300 mg - active: vedolizumab 300mg     excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate polysorbate 80 sucrose - treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf alpha) antagonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - brentuximab vedotin 50mg;  ;   - powder for injection - 50 mg - active: brentuximab vedotin 50mg     excipient: citric acid monohydrate polysorbate 80 sodium citrate dihydrate trehalose dihydrate - hodgkin lymphoma treatment of adult patients with cd30+ hodgkin lymphoma (hl) at higher risk of relapse or progression following asct. treatment of adult patients with relapsed or refractory cd30+ hl: 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - teduglutide 5mg; water for injection 0.5 ml - powder for injection with diluent - 5 mg - active: teduglutide 5mg excipient: dibasic sodium phosphate heptahydrate histidine hydrochloric acid mannitol monobasic sodium phosphate monohydrate sodium hydroxide water for injection active: water for injection 0.5 ml - revestive is indicated for the treatment of adult patients with short bowel syndrome (sbs) who are dependent on parenteral support. patients should be stable at least to 4 weeks on their parenteral support regimen before initiating teduglutide therapy

Israel - English - Ministry of Health

takeda israel ltd - albumin human - solution for infusion - albumin human 200 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

Israel - English - Ministry of Health

takeda israel ltd - albumin human - solution for infusion - albumin human 50 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

Israel - English - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 30 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Israel - English - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 90 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)